Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

Addex Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Addex and the SIB Swiss Institute of Bioinformatics Receive Innosuisse Grant to Repurpose Potent Dopamine Antagonist

Details:

CHF600K Innosuisse grant will support SIB's computational approaches to identify new therapeutic indications for ADX10061, a potent and selective dopamine D1 receptor antagonist.

Lead Product(s): ADX10061

Therapeutic Area: Neurology Product Name: ADX10061

Highest Development Status: Discovery Product Type: Small molecule

Partner/Sponsor/Collaborator: Innosuisse

Deal Size: $0.6 million Upfront Cash: Undisclosed

Deal Type: Funding August 27, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY